Monitor for future announcements regarding progression to commercialization or licensing terms with Tate & Lyle, as well as any follow-on CDMO agreements that could generate revenue.
Price Chart
Executive Summary
BioHarvest Sciences announced a key milestone with partner Tate & Lyle in their next-generation sweetener development programme, demonstrating that BioHarvest's Botanical Synthesis platform can produce the targeted sweetening solution. This is a positive technical validation of the platform's capabilities but remains an early-stage development milestone with no disclosed financial terms or revenue impact.
Key Facts
- Tate & Lyle and BioHarvest reached a key milestone in their next-generation sweetener development programme.
- The programme demonstrated that BioHarvest's Botanical Synthesis platform is capable of producing the targeted next-generation sweetening solution.
- The milestone builds on the expanded collaboration announced in May 2026.
- No financial terms, revenue projections, or commercialization timelines were disclosed.
- The filing is a 6-K with a press release dated October 8, 2026.
Financial Impact
No financial figures disclosed; the milestone is technical/developmental with no revenue or deal value stated.
Risk Factors
- No guarantee the developed sweetener will be commercialized or generate revenue.
- Development programmes may not proceed past the contracted stage.
- Forward-looking statements caution that actual results may differ materially.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001723464-26-000058 |
| Document: bhsc_6k.htm | 0001723464-26-000058 |
| Document: 0001723464-26-000058-index-headers.html | 0001723464-26-000058 |
| Document: 0001723464-26-000058-index.html | 0001723464-26-000058 |
| Document: 0001723464-26-000058.txt | 0001723464-26-000058 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | 6-K | $1.75 $1.67 | ▼ −4.18% | ▼ −4.64% | $1.70 (−2.58%) |
Oct 8, 2026 19d ago | 6-K | $1.50 $1.70 | ▲ +13.71% | ▲ +13.99% | $1.70 (+13.71%) |
Sep 15, 2026 6w ago | 6-K | $1.66 $1.46 | ▼ −12.05% | ▼ −14.61% | $1.70 (+2.41%) |
Sep 14, 2026 6w ago | 6-K | $1.78 $1.51 | ▼ −14.93% | ▼ −17.04% | $1.70 (−4.23%) |
Jul 15, 2026 14w ago | 6-K | $2.85 $2.18 | ▼ −23.51% | ▼ −22.53% | $1.70 (−40.35%) |
Jun 18, 2026 18w ago | 6-K | $3.26 $2.75 | ▼ −15.64% | ▼ −13.98% | $1.70 (−47.85%) |
May 28, 2026 21w ago | 6-K | $3.90 $3.56 | ▼ −8.72% | ▼ −8.67% | $1.70 (−56.41%) |
May 14, 2026 23w ago | 6-K | $4.16 $3.82 | ▼ −8.17% | ▼ −7.46% | $1.70 (−59.13%) |
May 14, 2026 23w ago | 6-K | $4.16 $3.82 | ▲ +8.17% | ▲ +7.46% | $1.70 (+59.13%) |
May 14, 2026 23w ago | 6-K | $4.16 $3.82 | ▼ −8.17% | ▼ −7.46% | $1.70 (−59.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers